Daniel C. Adelman
118 works · 4,575 citations · h-index 35
Top works
- Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
- Down-regulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody
- Immediate Hypersensitivity Reactions to Beta-Lactam Antibiotics
- Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data
- Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo.
- Imipenem cross-reactivity with penicillin in humans
- Down-Regulation of Human Basophil IgE and FCεRIα Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo
- Neuroimmunology
- The neuropsychiatric manifestations of systemic lupus erythematosus: An overview
- Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects
- Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation.
- Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients With Celiac Disease
- Serum IgE Level Drives Basophil and Mast Cell IgE Receptor Display
- Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
- Photoangioplasty for Human Peripheral Atherosclerosis
- Manual of Allergy and Immunology
- Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy
- The Cross-Reactivity and Immunology of ??-Lactam Antibiotics
- Phase I Drug and Light Dose-Escalation Trial of Motexafin Lutetium and Far Red Light Activation (Phototherapy) in Subjects With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention and Stent Deployment
- No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease